Abstract 51P
Background
Chromosomal instability (CIN) is hallmark of cancer associated to progression and aggressiveness in prostate cancer (PCa). In the search of the mechanisms controlling CIN, long non-coding RNAs (lncRNAs) have shown to play important roles in maintaining genome stability, nevertheless, characterization of these transcripts and the networks they control in CIN regulation is still poorly understood.
Methods
RNA-seq data from the prostate cell lines PrEC (stable) and LNCaP (unstable) was analyzed to find novel lncRNAs associated with CIN. Afterwards, experimental validation of the results in PrEC and LNCaP was performed with RT-qPCR and western blot. For the functional experiments, lncRNA knockdown (KD) was performed by transfecting cells with antisense oligonucleotides (ASOs) targeting the lncRNA of interest, followed by karyotyping to assess CIN in the transfected cells. Confirmation of the lncRNA KD was performed by qPCR.
Results
After analyzing and comparing RNA-Seq data from PrEC and LNCaP, a novel lncRNA was discovered in chromosome 3. This nuclear-retained transcript is adjacent to the protein coding gene RFC4, a gene associated to CIN that participates in DNA repair and replication. RT-qPCR analysis showed that while the lncRNA is upregulated in PrEC, RFC4 is downregulated, the opposite pattern was found in LNCaP, suggesting the lncRNA as a cis-repressor of RFC4. The functional experiments confirmed that the lncRNA is a transcriptional repressor of RFC4 but also a regulator of genome stability. After KD of the lncRNA in the stable cell line PrEC, an increase in RFC4 expression was observed as well as an increased number of tetraploid cells, suggesting CIN induction after lncRNA KD. To understand how the lncRNA regulates genome stability, RNA-Seq was performed in the KD experiments showing that lncRNA KD induced disruption of different pathways needed for proper DNA replication and chromosome segregation.
Conclusions
Together our results indicate that the novel lncRNA is a regulator of CIN through regulation of RFC4 and pathways important for maintaining genome stability. The lncRNA adjacent to the protein coding gene RFC4 could be a novel biomarker for PCa progression.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Unidad de Investigación Biomédica en Cáncer - Instituto Nacional de Cancerología - Instituto de Investigaciones Biomédicas - UNAM.
Funding
Unidad de Investigación Biomédica en Cáncer - Instituto Nacional de Cancerología - Instituto de Investigaciones Biomédicas - UNAM - CONACyT.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract